umbilical cord mesenchymal stem cells / Jackson Health System, University of Miami, The Cure Alliance - LARVOL DELTA

CATO: Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Roberto Bolli | Not yet recruiting ➔ Recruiting

Enrollment open • Stroma • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Heart Failure

CATO: Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Roberto Bolli

New P2 trial • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Heart Failure

Umbilical Cord-derived Mesenchymal Stem Cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients. (PubMed, Eur Rev Med Pharmacol Sci) - "These observations suggest that sTNFR2 plays a mechanistic role in mediating UC-MSC effect on TNFα and TNFβ plasma levels, determining a decrease in inflammation in COVID-19 ARDS."

Clinical • Journal • Acute Respiratory Distress Syndrome • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Oncology • Pulmonary Disease • Respiratory Diseases • TNFA

Use of UC-MSCs for COVID-19 Patients (clinicaltrials.gov) - P1/2; N=24; Completed; Sponsor: Camillo Ricordi; Active, not recruiting ➔ Completed

Clinical • Trial completion • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

Use of UC-MSCs for COVID-19 Patients (clinicaltrials.gov) - P1/2; N=24; Active, not recruiting; Sponsor: Camillo Ricordi; Recruiting ➔ Active, not recruiting; Trial completion date: May 2022 ➔ Dec 2020; Trial primary completion date: Apr 2021 ➔ Oct 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

Use of UC-MSCs for COVID-19 Patients (clinicaltrials.gov) - P1/2; N=24; Recruiting; Sponsor: Camillo Ricordi; Trial completion date: May 2021 ➔ May 2022; Trial primary completion date: Dec 2020 ➔ Apr 2021

Clinical • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

Use of UC-MSCs for COVID-19 Patients (clinicaltrials.gov) - P1/2; N=24; Recruiting; Sponsor: Camillo Ricordi

Clinical • New P1/2 trial • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases